Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE106561 | GEO | 2018/11/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [ChIP-Seq]

Project description:Endocrine therapies in prostate cancer (PCa) treatment block androgen receptor (AR) function, but are palliative as tumors progress to a lethal, castration-resistant state (CRPC). CRPC remains dependent on AR signaling, which can act through the full-length AR (ARfl) or constitutively active splice variants, e.g. ARv7. We show here that both ARfl and ARv7 bind to the same genomic region and heterodimerize in a CRPC cell line model, but regulate distinct transcriptomes. ARv7, unlike ARfl, preferentially represses transcription and demonstrates an increased affinity for co-repressors, decreased chromatin residence time and lower dependence on FOXA1 binding. We identified a group of ARv7-repressed genes, including the UDP-galactosyltransferase B4GALT1 that are down-regulated during PCa progression and important for CRPC growth. In conclusion, we propose that ARv7 acts as a transcriptional repressor of genes that limit proliferation, a function that should be targeted in CRPC patients.

2018-11-02 | GSE106559 | GEO

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [RNA-Seq]

2018-11-02 | GSE106560 | GEO

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Project description:Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease, but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially CRPC remains dependent on androgen receptor (AR) signaling, often through increased expression of full-length AR (ARfl) or expression of dominantly active splice variants such as ARv7. We show in ARv7-dependent CRPC models that ARv7 binds together with ARfl to repress transcription of a set of growth-suppressive genes. Expression of the ARv7-repressed targets and ARv7 protein expression are negatively correlated and predicts for outcome in PCa patients. Our results provide insights into the role of ARv7 in CRPC and define a set of potential biomarkers for tumors dependent on ARv7.

| S-EPMC7246081 | biostudies-literature

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer

Project description:ARv7 represses tumor suppressors genes in castration-resistant prostate cancer

| PRJNA417248 | ENA

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [ChIP-Seq]

Project description:ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [ChIP-Seq]

| PRJNA417256 | ENA

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [RNA-Seq]

Project description:ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [RNA-Seq]

| PRJNA417254 | ENA

LSD1 promotes castration-resistant prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-06-30 | E-GEOD-77763 | biostudies-arrayexpress

Targeting the MLL complex in castration-resistant prostate cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-02-27 | E-GEOD-60842 | biostudies-arrayexpress

AR-V7 targets the oncogenic genes in castration resistant prostate cancer.

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-11-02 | GSE122924 | GEO

LSD1 promotes castration-resistant prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-06-30 | GSE77763 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data